Publications

The following posters and presentations regarding OncoSec’s technology and clinical data have been presented at several scientific conferences and meetings

Keystone Poster

Clinical and biomarker analyses of a phase II study of intratumoral tavokinogene telseplasmid (pIL-12) plus pembrolizumab in stage III/IV melanoma patients predicted to not respond to anti-PD-1

SITC 2017

Download Poster

Download the Handout

Keystone Poster

Intratumoral Administration Of A Multigene Construct By Electroporation
Can Effectively Modulate Anti-Tumor Response In A Murine B16.f10 Model

Download Poster

Clinical Immune Monitoring and Biomarker Data of Tavo Monotherapy Compared to Tavo with Pembrolizumab in Metastatic Melanoma Supports the Rationale for Combination Therapy

9th Annual World Congress of Melanoma – A Joint Meeting with the Society of Melanoma Research

Download the Presentation 

 

AACR 2017 Poster Image

Intratumoral Delivery of a P2A-linked Bicistronic IL-12 Construct Leads to High Intratumoral Expression and Systemic Anti-tumor Response

American Association of Cancer Research (AACR) Annual Meeting 2017

Download the Poster

Keystone Poster

Intratumoral Electroporation-Mediated IL-12 Gene Therapy can Enhance Tumor Immunogenicity

Keystone Symposia Conference “Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology” 2017

Download the Poster

handoutascositc

Immune Monitoring Outcomes of Patients with Stage III/IV Melanoma Treated with a Combination of Pembrolizumab and Intratumoral Plasmid Interleukin 12 (pIL-12)

ASCO-SITC 2017

Download the Handout

Keystone Poster

Phase II Study of Intratumoral Plasmid Interleukin 12 (pIL-12) with Electroporation

SITC 2016

Download Poster

Download the Handout

Eurogin 2016 Presentation

Intratumoral IL-12 Therapy in HNSCC

EUROGIN 2016

Download the Poster

Helix Poster

A Novel Applicator for Endoscopic Gene Electro-Transfer

AACR Engineering and Physical Sciences in Oncology

Download the Poster

Feedback Poster

Feedback Optimized Gene Electro-Transfer for Immunotherapy

AACR Engineering and Physical Sciences in Oncology

Download the Poster

r113_9_aacr_2015

Priming response to anti-PD1/PDL1 blockade with intratumoral electroporation of plasmid IL-12 in advanced melanoma

American Association for Cancer Research Annual Meeting 2016

Download the Presentation

r113_9_aacr_2015

In vivo Intratumoral Electroporation of Gp96-Ig/Fc-OX40L Stimulates CD8+ T cell Cross Priming to Tumor-Specific Neoantigens

American Association for Cancer Research Annual Meeting 2016

Download the Poster

Intratumoral Delivery of Interleukin-12 DNA via In Vivo Electroporation Leads to Regression of Injected and Non-Injected Tumors in Merkel Cell Carcinoma

2015 European Cancer Congress

Download the Presentation 

Development of a Catheter-Based Applicator for Immuno-Oncology

First World Congress on Electroporation and Pulsed Electric Fields in Biology, Medicine and Food & Environmental Technologies

Download the Poster 

Advances in Clinical Electroporation: Tissue Sensing, Feedback Control, and Catheter Technology

First World Congress on Electroporation and Pulsed Electric Fields in Biology, Medicine and Food & Environmental Technologies

Download the Presentation 

Immune Correlates of Intratumoral IL-12 Electroporation

European Society for Medical Oncology 2014 Annual Meeting

Download the Poster 

Systemic Anti-Tumor Effect and Clinical Response in a Phase 2 Trial of Intratumoral Electroporation of Plasmid Interleukin-12 in Patients with Advanced Melanoma

American Society of Clinical Oncology 2014 Annual Meeting

Download the Poster 

Phase II OMS

Intratumoral electroporation of plasmid interleukin-12: efficacy and biomarker analyses from a phase 2 study in melanoma (OMS-I100)

Melanoma Bridge Meeting 2014

Download the Presentation

OncoSec’s scientists and researchers from collaborating organizations have published several scientific articles regarding intratumoral immunotherapies and electroporation DNA delivery in peer-reviewed journals.

Chen, DS. et. al. “Oncology Meets Immunology: The Cancer-Immunity Cycle.” Immunity. 2013 Jul 25; 39 (1):1–10. DOI: dx.doi.org/10.1016/j.immuni.2013.07.012.

Daud AI, Pierce, RH, et al. “Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma.” J Clin Invest. 2016 Aug 15. DOI:10.1172/JCI87324.

Daud AI, et. al. “Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma.” J Clin Oncol 26:5896-5903. DOI: 10.1200/JCO.2007.15.6794.

Herbst RS, et. al. “Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.” Nature. 2014 Nov27;515(7528): 563–567. DOI: 10.1038/nature14011.

Kerkar SP, et. al. “IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors.” J Clin Invest. 2011;121(12):4746–4757. DOI: 10.1172/JCI58814.

Kohrt HE, et. al. “Combination strategies to enhance antitumor ADCC.” Immunotherapy. 2012 May; 4(5): 511–527. DOI: 10.2217/imt.12.38.

Lucas ML, et. al. “IL-12 Plasmid Delivery by in Vivo Electroporation for the Successful Treatment of Established Subcutaneous B16.F10 Melanoma.” Mol Ther. 2002 Jun;5(6):668-75. DOI: 10.1006/mthe.2002.0601.

Marabelle, A. et. al. “Intratumoral Immunization: A New Paradigm for Cancer Therapy.” Clin Cancer Res 2014;20:1747-1756. DOI: 10.1158/1078-0432.CCR-13-2116.

Pardoll DM. “The blockade of immune checkpoints in cancer immunotherapy.” Nat Rev Cancer. 2012 Mar 22;12(4):252-64. DOI: 10.1038/nrc3239.

Pierce RH, et. al. “In-situ tumor vaccination: Bringing the fight to the tumor.” Human Vaccines & Immunotherapeutics. 2015; 11(8): 1901-1909. DOI: 10.1080/21645515.2015.1049779.

Sin J, et. al. “Intratumoral electroporation of IL-12 cDNA eradicates established melanomas by Trp2180–188-specific CD8+ CTLs in a perforin/granzyme-mediated and IFN-c-dependent manner: application of Trp2180–188 peptides.” Cancer Immunol Immunother. 2012;61:1671–1682. DOI: 10.1007/s00262-012-1214-8.

Spranger S, et. al. “Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T-cells.” Sci Transl Med. 2013; 5, 200ra116. DOI: 10.1126/scitranslmed.3006504.

Tumeh PC, et. al. “PD-1 blockade induces responses by inhibiting adaptive immune resistance.” Nature. 2014 Nov 27;515(7528):568-71. DOI: 10.1038/nature13954.

Real Time Web Analytics